DK200201741A - Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum - Google Patents

Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum Download PDF

Info

Publication number
DK200201741A
DK200201741A DK200201741A DKPA200201741A DK200201741A DK 200201741 A DK200201741 A DK 200201741A DK 200201741 A DK200201741 A DK 200201741A DK PA200201741 A DKPA200201741 A DK PA200201741A DK 200201741 A DK200201741 A DK 200201741A
Authority
DK
Denmark
Prior art keywords
plasmodium
protein
merozoite surface
falcinarum
surface protein
Prior art date
Application number
DK200201741A
Other languages
Danish (da)
English (en)
Inventor
Theisen Michael
Jepsen Soeren
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Priority to DK200201741A priority Critical patent/DK200201741A/da
Publication of DK200201741A publication Critical patent/DK200201741A/da
Priority to PCT/DK2003/000759 priority patent/WO2004043488A1/en
Priority to HK06102595.9A priority patent/HK1080754B/en
Priority to JP2005506641A priority patent/JP4573773B2/ja
Priority to AT03810941T priority patent/ATE432081T1/de
Priority to ES03810941T priority patent/ES2326415T3/es
Priority to CN2003801031543A priority patent/CN1741815B/zh
Priority to DE60327801T priority patent/DE60327801D1/de
Priority to CA2505724A priority patent/CA2505724C/en
Priority to DK03810941T priority patent/DK1567189T3/da
Priority to BR0315205-7A priority patent/BR0315205A/pt
Priority to EP03810941A priority patent/EP1567189B1/de
Priority to AU2003275949A priority patent/AU2003275949B2/en
Priority to US11/128,660 priority patent/US7749507B2/en
Priority to ZA200504415A priority patent/ZA200504415B/en
Priority to US12/793,575 priority patent/US20110020387A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK200201741A 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum DK200201741A (da)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
AU2003275949A AU2003275949B2 (en) 2002-11-12 2003-11-06 Malaria vaccine
CN2003801031543A CN1741815B (zh) 2002-11-12 2003-11-06 疟疾疫苗
CA2505724A CA2505724C (en) 2002-11-12 2003-11-06 Malaria vaccine
JP2005506641A JP4573773B2 (ja) 2002-11-12 2003-11-06 マラリア・ワクチン
AT03810941T ATE432081T1 (de) 2002-11-12 2003-11-06 Malaria-vakzine
ES03810941T ES2326415T3 (es) 2002-11-12 2003-11-06 Vacuna contra la malaria.
PCT/DK2003/000759 WO2004043488A1 (en) 2002-11-12 2003-11-06 Malaria vaccine
DE60327801T DE60327801D1 (de) 2002-11-12 2003-11-06 Malaria-vakzine
HK06102595.9A HK1080754B (en) 2002-11-12 2003-11-06 Malaria vaccine
DK03810941T DK1567189T3 (da) 2002-11-12 2003-11-06 Malariavaccine
BR0315205-7A BR0315205A (pt) 2002-11-12 2003-11-06 Vacina baseada em antìgeno contra malária, proteìna de fusão, processo para preparação da mesma, ácido nucleico, e, uso do mesmo
EP03810941A EP1567189B1 (de) 2002-11-12 2003-11-06 Malaria-vakzine
US11/128,660 US7749507B2 (en) 2002-11-12 2005-05-12 Malaria vaccine
ZA200504415A ZA200504415B (en) 2002-11-12 2006-01-17 Malaria vaccine
US12/793,575 US20110020387A1 (en) 2002-11-12 2010-06-03 Malaria vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
DKPA200301307 2003-09-11

Publications (1)

Publication Number Publication Date
DK200201741A true DK200201741A (da) 2003-09-16

Family

ID=32313776

Family Applications (2)

Application Number Title Priority Date Filing Date
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
DK03810941T DK1567189T3 (da) 2002-11-12 2003-11-06 Malariavaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03810941T DK1567189T3 (da) 2002-11-12 2003-11-06 Malariavaccine

Country Status (13)

Country Link
US (2) US7749507B2 (de)
EP (1) EP1567189B1 (de)
JP (1) JP4573773B2 (de)
CN (1) CN1741815B (de)
AT (1) ATE432081T1 (de)
AU (1) AU2003275949B2 (de)
BR (1) BR0315205A (de)
CA (1) CA2505724C (de)
DE (1) DE60327801D1 (de)
DK (2) DK200201741A (de)
ES (1) ES2326415T3 (de)
WO (1) WO2004043488A1 (de)
ZA (1) ZA200504415B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
US7488489B2 (en) 2004-08-03 2009-02-10 Institut Pasteur Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies
US9119815B2 (en) * 2009-05-05 2015-09-01 Cadila Healthcare Limited Combined measles-malaria vaccine
CA2767453C (en) 2009-07-15 2018-10-09 The University Of British Columbia Neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals
EP2385107B1 (de) 2010-05-03 2016-08-24 Institut Pasteur Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria
EP2763694B1 (de) * 2011-10-04 2018-01-03 Statens Serum Institut Herstellung eines cysteinreichen proteins
EP2785369A4 (de) * 2011-11-30 2015-07-01 Univ California Immunogene plasmodium-falciparum-antigenzusammensetzungen und verwendungen davon
CN102533677B (zh) * 2012-01-10 2013-07-24 特菲(天津)生物医药科技有限公司 一种疟疾疫苗及其制备方法
KR102128413B1 (ko) 2012-01-19 2020-07-01 더 유니버시티 오브 브리티쉬 콜롬비아 3' 적도방향 불소 치환된 뉴라미니다제 저해제 화합물 및 항바이러스제로 사용하기 위한 이의 조성물 및 방법
CN105628928A (zh) * 2014-11-11 2016-06-01 深圳国际旅行卫生保健中心 可用于辅助诊断疟疾的试剂盒
CN105652009B (zh) * 2014-11-11 2018-04-24 中国科学院苏州纳米技术与纳米仿生研究所 可用于辅助诊断疟疾的试剂盒
MX2018014253A (es) 2016-05-19 2019-11-11 Univ Pennsylvania Inmunógenos de malaria sintéticos, combinaciones de estos y su uso para prevenir y tratar infecciones de malaria.
BR112019001115A2 (pt) * 2016-07-21 2019-06-25 Vac4All Pte Ltd proteínas de biofusão como vacinas anti-malária

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002811A1 (en) * 1988-09-16 1990-03-22 Statens Seruminstitut A malaria antigen
US5231168A (en) * 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
DK519188D0 (da) * 1988-09-16 1988-09-16 Statens Seruminstitut Kemisk forbindelse
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
EP1156825A2 (de) * 1999-02-25 2001-11-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogene enthaltend ein peptid und einen von h.influenzae protein d abstammenden träger
WO2002092628A2 (fr) * 2001-05-16 2002-11-21 Institut Pasteur Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum

Also Published As

Publication number Publication date
EP1567189A1 (de) 2005-08-31
BR0315205A (pt) 2005-08-16
US20060024324A1 (en) 2006-02-02
JP4573773B2 (ja) 2010-11-04
CN1741815B (zh) 2010-05-26
AU2003275949A1 (en) 2004-06-03
US20110020387A1 (en) 2011-01-27
DE60327801D1 (de) 2009-07-09
CN1741815A (zh) 2006-03-01
CA2505724A1 (en) 2004-05-27
US7749507B2 (en) 2010-07-06
WO2004043488A1 (en) 2004-05-27
AU2003275949B2 (en) 2008-06-05
HK1080754A1 (en) 2006-05-04
ES2326415T3 (es) 2009-10-09
JP2006512926A (ja) 2006-04-20
ZA200504415B (en) 2006-03-29
ATE432081T1 (de) 2009-06-15
CA2505724C (en) 2015-06-30
EP1567189B1 (de) 2009-05-27
DK1567189T3 (da) 2009-09-14

Similar Documents

Publication Publication Date Title
DK200201741A (da) Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
Acquah et al. Transmission-blocking vaccines: old friends and new prospects
Mahanty et al. Progress in the development of recombinant and synthetic blood-stage malaria vaccines
Moelans et al. A novel protein antigen of the malaria parasite Plasmodium falciparum, located on the surface of gametes and sporozoites
Eichinger et al. Circumsporozoite protein of Plasmodium berghei: gene cloning and identification of the immunodominant epitopes
ES2218520T3 (es) Antigenos de plasmodium falciparum inductores de anticuerpos protectores.
Renia et al. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge
Fidock et al. Cloning and characterization of a novel Plasmodium falciparum sporozoite surface antigen, STARP
Sinnis et al. Cell invasion by the vertebrate stages of Plasmodium
Lobo et al. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies
Ramasamy Molecular basis for evasion of host immunity and pathogenesis in malaria
FR2744724B1 (fr) Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
Webster et al. Progress with new malaria vaccines
JP2006512926A5 (de)
Yoshida et al. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite
WO2003016354A3 (en) Recombinant anti-plasmodium falciparum antibodies
Belperron et al. Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum
RU2007109608A (ru) Вакцины, содержащие антиген plasmodium
Kaslow et al. Malaria transmission-blocking vaccines
Burns Jr et al. A protective glycosylphosphatidylinositol-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains
US5217898A (en) Expression of the P. falciparum transmission-blocking antigen in yeast
BR9604989A (pt) Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção
Zhang et al. Construction and evaluation of a multistage combination vaccine against malaria
DE60235044D1 (de) REKOMBINANTES, 250 kDa GROSSES ANTIGEN AUS SPOROZOITEN/MEROZOITEN VON EIMERIA MAXIMA CODIERENDE NUKLEINSÄUREN UND IHRE VERWENDUNGEN
EP0254862A1 (de) Impfstoffe gegen protozoischen Parasiten

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment